ТРИМЕТАЗИДИН В КОМБИНИРОВАННОЙ ТЕРАПИИ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА, ПЕРЕНЕСШИХ ИНФАРКТ МИОКАРДА

Аннотация

Несмотря на постоянное совершенствование методов обследования и лечения, уровень смертности от ИБС сохраняется высоким, в связи с чем ведутся поиски и разработки новых подходов к ведению больных ИБС. Эпидемиологические исследования, проведенные среди населения Узбекистана, показали, что более 26% лиц в возрасте старше 40 лет страдают артериальной гипертонией (АГ), которая является причиной мозгового инсульта, острого инфаркта миокарда, сердечной недостаточности; около 11% страдают различными формами ИБС. В Узбекистане ежегодно регистрируется 8000 случаев острого инфаркта миокарда, около 60% пациентов умирают на догоспитальном этапе. Поэтому, это является актуальной проблемой не только клинической, но и научной медицины. Появление в клинической практике препаратов метаболического действия стало выдающимся событием в кардиологии. Ключевые слова: сердечно-сосудистая система, ишемическая болезнь сердца, инфаркт миокарда. Kobilova Nigina Akmalovna Assistant of the Department of Internal Medicine, Faculty of Postgraduate Education, Samarkand State Medical Institute, Samarkand, Uzbekistan TRIMETAZIDINE IN COMBINED THERAPY OF ISCHEMIC HEART DISEASE WITH MYOCARDIAL INFARCTION ANNOTATION Despite the constant improvement of methods of examination and treatment, the mortality rate from coronary artery disease remains high, and therefore the search and development of new approaches to the management of patients with coronary artery disease are underway. Epidemiological studies carried out among the population of Uzbekistan have shown that more than 26% of people over the age of 40 suffer from arterial hypertension (AH), which is the cause of cerebral stroke, acute myocardial infarction, heart failure; about 11% suffer from various forms of ischemic heart disease. In Uzbekistan, 8000 cases of acute myocardial infarction are registered annually, about 60% of patients die at the pre-hospital stage [3]. Therefore, this is an urgent problem not only in clinical, but also in scientific medicine. The appearance of metabolic drugs in clinical practice has become an outstanding event in cardiology. Key words: CVS (cardiovascular system), ischemic heart disease, myocardial infarction. Kobilova Nigina Akmalovna Diplomdan keying ta`lim fakulteti terapiya kafedrasi assistenti Samarqand Davlat Tibbiyot Instituti, Samarqand, O’zbekiston MIOKARD INFARKTI O`TKAZGAN YURAK ISHEMIK KASLLIGI BOR BEMORLARDA TRIMETAZIDINNING KOMBINIRLANGAN TERAPIYASI ANNOTATSIYA Tekshiruv va davolash usullarining doimiy takomillashtirilishiga qaramay, yurak-qon tomir kasalliklaridan o'lim darajasi yuqoriligicha qolmoqda va shuning uchun yurak ishemik kasalligi bilan og'rigan bemorlarni davolashning yangi yondashuvlarini izlash va ishlab chiqish davom etmoqda. O‘zbekiston aholisi o‘rtasida olib borilgan epidemiologik tadqiqotlar shuni ko‘rsatdiki, 40 yoshdan oshgan aholining 26% dan ortig‘i miya insultlari, o‘tkir miokard infarkti, yurak yetishmovchiligining sababi bo‘lgan arterial gipertenziya (AG); taxminan 11% yurak ishemik kasalligining turli shakllaridan aziyat chekadi. O‘zbekistonda har yili 8000 ga yaqin o‘tkir miokard infarkti qayd etiladi, bemorlarning 60 foizga 31 ЖУРНАЛ КАРДИОРЕСПИРАТОРНЫХ ИССЛЕДОВАНИЙ | JOURNAL OF CARDIORESPIRATORY RESEARCH №4 | 2021 yaqini kasalxonaga yotqizishdan oldingi bosqichda vafot etadi. Shuning uchun bu nafaqat klinik, balki ilmiy tibbiyotda ham dolzarb muammodir. Metabolik dorilarning klinik amaliyotda paydo bo'lishi kardiologiyada ajoyib voqea bo'ldi. Kalit so’zi: Yurak qon-tomir tizimi, yurak ishemik kasalligi, miokard infarkti. Cardiovascular diseases (CVD) are the leading cause of nonviolent ejection fraction of less than 50%... The patients were divided into 2 death in the world. Among them, ischemic heart disease is in the lead - groups. The first group (comparison group) included 19 (36%) patients in 2020 it affects 126 million people worldwide, this is 16% of all deaths (men - 14 (74%), women - 5 (26%)) who received only basic therapy [4]. Men are susceptible to coronary artery disease more often than (beta-blockers, ACE inhibitors, anticoagulants, antianginal drugs) ... women [4]. Clinical manifestations of coronary artery disease include The second group included 33 (63%) patients (men - 22 (67%), women asymptomatic myocardial ischemia, angina pectoris, acute coronary - 11 (33%)) who, along with basic therapy, received trimetazidine syndromes (unstable angina pectoris, myocardial infarction) and sudden (predizin, Gedeon Richter, Hungary) at a dose of 35 mg 2 times day for cardiac death [5]. Despite the constant improvement of examination and 3 months. In the first grouppatients with bad habits accounted for 9 treatment methods, the mortality rate from coronary artery disease (47.3%), obese patients - 6 (31.6%). Of the concomitant pathology, remains high, and therefore the search and development of new most patients with AH - 9 (47.4%), with diseases of the gastrointestinal approaches to the management of patient